Deerfield Management’s Zevra Therapeutics ZVRA Stock Holding History

Deerfield Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,849	Closed	-$81.3K	–	164
2025 Q1	$81.3K	Buy	+10,849	New	+$86.2K	﹤0.01%	103
2020 Q2	–	Sell	-26,163	Closed	-$94K	–	105
2020 Q1	$94K	Sell	26,163 -6,193	-19%	-$34.2K	﹤0.01%	90
2019 Q4	$196K	Sell	32,356 -10,901	-25%	-$86.6K	0.01%	76
2019 Q3	$477K	Buy	+43,257	New	+$782K	0.02%	91
2017 Q3	–	Sell	-44,038	Closed	-$2.82M	–	99
2017 Q2	$2.82M	Sell	44,038 -23,740	-35%	-$1.56M	0.15%	77
2017 Q1	$5.31M	Hold	67,778	–	–	0.2%	85
2016 Q4	$3.2M	Hold	67,778	–	–	0.13%	81
2016 Q3	$4.87M	Sell	67,778 -21,003	-24%	-$1.49M	0.23%	61
2016 Q2	$5.65M	Hold	88,781	–	–	0.22%	70
2016 Q1	$20.6M	Hold	88,781	–	–	0.88%	40
2015 Q4	$28.2M	Hold	88,781	–	–	1.14%	37
2015 Q3	$27.5M	Buy	88,781 +21,003	+31%	+$6.43M	1.06%	37
2015 Q2	$19.9M	Buy	+67,778	New	+$14.8M	0.66%	54

Other funds holding ZVRA

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Deerfield Management's ZVRA Position: Q2 2025 in Review

Deerfield Management sold out of Zevra Therapeutics (ZVRA) in Q2 2025, closing a stake of 10,849 shares — an estimated $81.3K sold.

Deerfield Management first reported a position in ZVRA in Q2 2015 and held it in 13 quarters. The position peaked at $28.2M in Q4 2015. 120 funds tracked by Wall St. Rank hold ZVRA as of Q2 2025.

Deerfield Management reported no remaining Zevra Therapeutics position as of Q2 2025 after selling out during the quarter.
Deerfield Management sold 10,849 Zevra Therapeutics shares in Q2 2025, an estimated $81.3K.
Deerfield Management first reported a position in Zevra Therapeutics in Q2 2015 and held it in 13 quarters.
Deerfield Management's Zevra Therapeutics position peaked at $28.2M in Q4 2015.
120 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2025.

Based on Deerfield Management's 13F filing for Q2 2025, filed 14 Aug 2025.